Rznomics Secures FDA RMAT Designation for Liver Cancer Candidate RZ-001
Monday, May 11, 2026
Rznomics has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration for RZ-001, its investigational therapy for hepatocellular carcinoma (HCC).
The RMAT programme was introduced by the FDA to support faster development and review of advanced therapies, including gene therapies, for serious or life-threatening diseases. To qualify, companies must provide preliminary clinical evidence showing the potential to address unmet medical needs.
The designation offers several regulatory benefits, including closer FDA guidance, eligibility for priority and rolling reviews, and access to accelerated approval pathways. The programme is intended to help bring innovative therapies to patients more quickly.
RZ-001 is an RNA-based oncology therapy developed using Rznomics’ proprietary trans-splicing ribozyme technology platform. The treatment is designed to replace cancer-specific RNA with therapeutic RNA, offering a different mechanism compared with conventional cancer therapies. The company stated that the platform aims to improve both tumour selectivity and safety for patients with limited treatment options.
The therapy previously received Orphan Drug Designation in 2024 and Fast Track Designation in 2025 for the treatment of HCC.
The FDA’s RMAT decision follows interim findings from a Phase 1b/2a clinical trial presented at the American Association for Cancer Research Annual Meeting 2026 in April 2026, which highlighted the clinical potential of RZ-001.
Rznomics plans to expand its development and partnership activities in the United States, including discussions with the FDA on clinical trial design, manufacturing and commercialisation strategies. The company also intends to strengthen global development efforts for RZ-001 as it targets the liver cancer treatment market.
Source: prnewswire.com
